First long-term results on efficacy and safety of long-acting pasireotide in combination with everolimus in patients with advanced carcinoids (NET) of the lung/thymus: Phase II LUNA trial.
Éric Baudin(Institut Gustave Roussy), Piero Ferollà(University of Perugia), Alfredo Berruti(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Catalin Bobirca(Novartis (Switzerland)), Mario Giuliano(Regione Campania), Wasat Mansoor(The Christie NHS Foundation Trust), Niamh Fagan(Novartis (Switzerland)), Kjell E. Öberg(Uppsala University Hospital), Erik Houtsma(Novartis (Switzerland))
Cited by 7
Related Papers
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary
|Neuroendocrinology|2012|869
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
|New England Journal of Medicine|2012|863